卡瑞利珠单抗联合含铂双药方案治疗晚期非小细胞肺癌患者的影响  

Influence of camrelizumab combined with platinum-containing dual-drug regimen in the treatment of patients with NSCLC

作　　者：常琴 王艳艳 李佳 贾燕丽 武琴琴 刘乐 郭淑明 马小军 CHANG Qin;WANG Yanyan;LI Jia;JIA Yanli;WU Qinqin;LIU Le;GUO Shuming;MA Xiaojun(Department of Respiratory and Critical Care and Sleep Medicine,Linfen Central Hospital,Linfen 041000,Shanxi,China;Hospital Office,Linfen Central Hospital,Linfen 041000,Shanxi,China)

机构地区：[1]临汾市中心医院呼吸与危重症和睡眠医学科,山西临汾041000 [2]临汾市中心医院院办,山西临汾041000

出　　处：《西部医学》2025年第4期538-542,共5页Medical Journal of West China

基　　金：山西省医学重点科研项目(2021XM19)。

摘　　要：目的探究卡瑞利珠单抗联合含铂双药方案治疗晚期非小细胞肺癌(NSCLC)患者的影响。方法回顾性分析我院2019年1月—2021年1月收治的NSCLC患者的临床资料,随机从接受培美曲塞与卡铂治疗的临床资料中抽取53例纳入对照组,从接受卡瑞利珠单抗结合含铂双药方案治疗的临床资料中抽取53例纳入观察组。记录治疗3疗程后两组患者临床症状缓解率及治疗期间毒副反应发生情况,比较两组患者治疗前、治疗3疗程后免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比值)、血清肿瘤标志物[神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)]、生活质量[肺癌患者生活质量量表(QLQ-LC43)]的变化;化疗结束后进行随访2年,对比两组远期疗效。结果治疗3疗程后,观察组症状缓解率高于对照组(P<0.05),毒副反应发生率比较差异无统计学(P>0.05);治疗3疗程后两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均降低,且观察组高于对照组(P<0.05),CD8^(+)水平、QLQ-LC43评分均升高,观察组低于对照组(P<0.05);治疗3疗程后两组血清NSE、CEA均降低,且观察组低于对照组(P<0.05);随访2年,观察组生存率高于对照组(t=0.047,P<0.05),观察组PFS长于对照组(P<0.05),观察组OS显著长于对照组(P<0.05)。结论卡瑞利珠单抗联合含铂双药方案对NSCLC患者的临床疗效显著,能有效降低血清肿瘤标志物水平,提高机体免疫力,有利于提高患者远期生存率。Objective To explore the influence of camrelizumab combined with platinum-containing dual-drug regimen in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods The clinical data of patients with NSCLC in the hospital were retrospectively analyzed from January 2019 to January 2021.53 patients who were treated with pemetrexed and carboplatin were randomly selected and included in control group,and 53 patients receiving camrelizumab combined with platinum-containing dual-drug regimen were enrolled as observation group.The clinical symptom relief rate after 3 courses of treatment and occurrence of toxic and side effects during treatment were recorded.The changes in immune function(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)ratio),serum tumor markers[neuron-specific enolase(NSE),carcinoembryonic antigen(CEA)]and quality of life[Quality of Life Questionnaire-Lung Cancer(QLQ-LC43)]were compared between the two groups before treatment and after 3 courses of treatment.Follow-up was conducted for 2 years after chemotherapy,and the long-term efficacy was compared.Results After 3 courses of treatment,the symptom relief rate and 2-year survival rate in observation group were significantly higher than those in control group(P<0.05),but there were no statistical differences in the incidence rates of toxic and side effects(P>0.05).The CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)level in both groups were decreased after 3 courses of treatment,and the indicators in observation group were higher than those in control group(P<0.05),and the CD8^(+)level and QLQ-LC43 score were increased,and the indicators in observation group were lower than those in control group(P<0.05).After 3 courses of treatment,serum NSE and CEA were declined in both groups,and the levels in observation group were lower than those in control group(P<0.05).After 2 years of follow-up,the mortality rate in observation group(11.32%)was significantly lower than that in control group(26.42%)(P<0.05),and the PFS with(9.37±1.24)months was significantly l

关 键 词：卡瑞利珠单抗 非小细胞肺癌 毒副反应 生存率 

分 类 号：R734.2[医药卫生—肿瘤]